Zevra Therapeutics (ZVRA) AI Stock Analysis

• Market Cap: $487.54M
• Dividend Yield: N/A
• Average Volume (3M): 2.44M
• Price to Earnings (P/E): 13.7
• Beta (1Y): 0.65
• Revenue Growth: 240.47%
• EPS Growth: N/A
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 56,297,535
• 10 Day Avg. Volume: 2,552,948
• 30 Day Avg. Volume: 2,436,184
• PEG Ratio: -0.05
• Price to Book (P/B): 9.72
• Price to Sales (P/S): 16.34
• P/FCF Ratio: -5.54
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 4.06
• Enterprise Value/Gross Profit: 5.05
• Enterprise Value/Ebitda: 5.09
• 1Y Price Target: $24.00
• Price Target Upside: 186.05% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $9.00 ▲(7.27% Upside)

Zevra Therapeutics' overall score is driven by strong revenue growth and reasonable valuation, offset by significant challenges in profitability and cash flow management. Technical indicators suggest a bearish trend, but the company's strategic initiatives and robust financial position provide a foundation for future growth.

Positive Factors

Revenue Growth

Sustained revenue growth indicates successful product adoption and market penetration, supporting long-term financial health and expansion.

European Market Expansion

Expanding into the European market could significantly increase Zevra's patient base and revenue potential, enhancing its global footprint.

Robust Financial Position

A strong cash position provides Zevra with the financial flexibility to invest in strategic priorities and withstand industry challenges.

Negative Factors

Profitability Challenges

Persistent profitability issues can hinder reinvestment in R&D and limit competitive positioning, affecting long-term growth potential.

Negative Cash Flows

Negative cash flows can strain liquidity and operational flexibility, potentially impacting the company's ability to fund future growth initiatives.

Slow Trial Enrollment

Slow trial enrollment can delay product development timelines, affecting future revenue streams and competitive advantage in the market.

Zevra Therapeutics Business Overview & Revenue Model

Company Description

Zevra Therapeutics (ZVRA) is a biopharmaceutical company focused on developing innovative therapies for rare and complex diseases. The company operates primarily in the biotechnology sector, harnessing advanced research and development to create treatments that address unmet medical needs. Zevra's core products include therapeutics aimed at conditions such as rare genetic disorders and central nervous system diseases, with a pipeline that reflects its commitment to addressing challenging health issues.

How the Company Makes Money

Zevra Therapeutics generates revenue through several key streams, primarily centered around the commercialization of its biopharmaceutical products. The company earns income from the sale of approved therapeutics, as well as potential licensing agreements and partnerships with larger pharmaceutical firms for the development and distribution of its products. Additionally, Zevra may engage in collaborative research agreements that provide funding in exchange for access to its innovative technologies and drug candidates. Significant partnerships with established players in the pharmaceutical industry enhance Zevra's financial stability and provide a pathway for future revenue growth through joint ventures and co-development agreements.

Zevra Therapeutics Financial Statement Overview

Summary

Zevra Therapeutics shows strong revenue growth, but profitability and cash flow challenges persist. The balance sheet reflects improved leverage, yet low returns on equity and negative cash flows hinder overall financial health.

Income Statement

Zevra Therapeutics shows a strong revenue growth rate of 36.07% in the TTM, indicating positive momentum. However, the company struggles with profitability, as evidenced by negative EBIT and EBITDA margins. The net profit margin has improved to 4.26% in the TTM, a significant recovery from previous negative margins, suggesting better cost management or revenue mix.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.53 in the TTM, reflecting a more balanced capital structure compared to previous years. However, the return on equity remains low at 3.95%, indicating limited profitability relative to shareholder equity. The equity ratio is stable, suggesting a solid asset base.

Cash Flow

Zevra Therapeutics faces challenges with negative operating and free cash flows, which have deteriorated further in the TTM. The free cash flow to net income ratio is slightly above 1, indicating that the company is generating enough free cash flow relative to net income, but the negative growth in free cash flow is concerning.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	84.39M	23.61M	27.46M	10.16M	28.65M	13.29M
Gross Profit	67.75M	16.20M	24.52M	9.94M	26.59M	11.98M
EBITDA	67.21M	-76.40M	-43.54M	-25.53M	-7.89M	-5.43M
Net Income	34.46M	-105.51M	-46.05M	-26.77M	-8.55M	-12.76M
Balance Sheet
Total Assets	270.12M	178.13M	172.33M	115.34M	132.94M	11.21M
Cash, Cash Equivalents and Short-Term Investments	199.51M	69.50M	67.74M	82.85M	112.35M	4.21M
Total Debt	62.72M	60.30M	43.77M	18.78M	1.61M	70.55M
Total Liabilities	136.95M	138.46M	110.46M	40.22M	5.82M	77.62M
Stockholders Equity	133.16M	39.67M	61.86M	75.12M	127.12M	-66.41M
Cash Flow
Free Cash Flow	-24.23M	-69.67M	-33.83M	-18.81M	10.34M	-1.97M
Operating Cash Flow	-23.36M	-69.67M	-33.53M	-18.72M	10.44M	-1.94M
Investing Cash Flow	12.43M	-22.16M	-17.39M	-36.72M	-15.52M	-33.00K
Financing Cash Flow	10.31M	82.11M	28.46M	8.35M	113.11M	2.74M

Zevra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVRA, the sentiment is Negative. The current price of 8.39 is below the 20-day moving average (MA) of 8.76, below the 50-day MA of 9.71, and below the 200-day MA of 9.11, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 40.25 is Neutral, neither overbought nor oversold. The STOCH value of 38.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZVRA.

Zevra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZVRA	57 Neutral	$487.54M	13.73	34.81%	―	240.47%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRTA	50 Neutral	$600.74M	-2.14	-67.63%	―	-91.16%	-112.24%
LXRX	48 Neutral	$476.05M	―	-45.92%	―	1255.21%	74.58%
OCGN	46 Neutral	$446.60M	―	-289.93%	―	14.26%	-23.34%
SLDB	44 Neutral	$458.11M	―	-86.83%	―	―	17.88%
CRVS	41 Neutral	$634.05M	―	-35.82%	―	―	79.27%

Zevra Therapeutics Corporate Events

Zevra Therapeutics Appoints Alicia Secor to Board

On December 2, 2025, Zevra Therapeutics announced the appointment of Alicia Secor to its Board of Directors, following the resignation of Wendy Dixon, PhD. Secor, with over thirty years of experience in the life sciences industry, is expected to contribute significantly to the company’s strategic goals and shareholder value. Dixon’s departure was amicable, with no disagreements with the company’s operations, policies, or practices.

Zevra Therapeutics CFO Resignation Announced

On November 20, 2025, Zevra Therapeutics announced that its Chief Financial Officer, R. LaDuane Clifton, will resign effective December 31, 2025, to pursue other opportunities. Clifton, who joined the company in 2015, played a key role in its transition to a commercial-stage company and leaves behind a strong financial foundation. The company has initiated a search for his successor.